Last edition
News about "Novartis"
Novartis Signs Deal with Synnovation Therapeutics to Explore Next-Gen Breast Cancer Treatment
Novartis has signed a deal with Synnovation Therapeutics to advance SNV4818, a next-generation PI3Kα inhibitor in phase-I/II trials, targeting HR+/HER2- breast cancer patients with PIK3CA mutations, addressing a significant unmet need.
Novartis | 20/03/2026 | By News Bureau
US FDA Approves Novartis' Cosentyx for Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
The FDA has approved Novartis’ Cosentyx for patients aged 12 years and above with moderate-to-severe Hidradenitis Suppurativa (HS), marking the therapy’s fourth paediatric indication and expanding treatment options with a differentiated IL-17A mechanism.
Novartis | 16/03/2026 | By News Bureau
Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria
Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.
Novartis | 19/02/2026 | By News Bureau | 141
Novartis Builds Global Biomedical Research Centre in San Diego
Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.
Novartis | 09/02/2026 | By News Bureau
Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026
Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.
Novartis | 05/02/2026 | By Darshana | 430
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Novartis | 19/01/2026 | By News Bureau | 179
Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies
Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.
Novartis | 13/01/2026 | By Darshana | 330
Novartis to Add Fourth US Radioligand Therapy Plant in Florida
Novartis will expand its US radioligand therapy manufacturing network with a new purpose-built facility in Winter Park, Florida, strengthening patient access across the southeastern US and supporting the company’s broader USD 23 billion investment in advanced manufacturing and oncology innovation.
Novartis | 12/01/2026 | By News Bureau | 183
Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.
Novartis | 22/12/2025 | By News Bureau | 214
Novartis Breaks Ground on Flagship Manufacturing Hub in North Carolina
Novartis has officially begun construction of its flagship manufacturing hub in North Carolina, reinforcing its commitment to end-to-end production of key medicines for US patients. The project, highlighted by FDA Commissioner Marty Makary and Governor Josh Stein, underscores Novartis’ ongoing investment and growth in the US pharmaceutical sector.
Novartis | 15/12/2025 | By News Bureau | 372
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy